Kornimate/medical-research-clean huggingface dataset:
lifestyle intervention to prevent the recurrence of gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus (GDM)

Summary: gestational diabetes mellitus(gdm) is a commom complication during pregnancy and associated with various adverse pregnancy outcomes for both the mother and her offspring. imoportantly, with the gradual opening of a two-child policy, more and more chinese women of reproductive age enter pregnancy have a history of gdm. our previous study showed that regular exercise commenced in early pregnancy is effective in reducing the risk of developing gdm in chinese overweight and obese pregant women. thus, in this study, we want to evaluate the effect of lifestyle intervention with detailed information on how to eat and how to diet in preventing the recurrence of gdm.

gestational diabetes mellitus(gdm) is a commom complication during pregnancy. and the incidence has reached as high as 19.2% in china. gdm is associated with various adverse pregnancy outcomes for both the mother and her offspring, and not only during the perinatal phase, but also in the long term.thus finding effective way to reduce the risk of gdm is of great importance,especial for women with high gdm risk factors. gdm history is one of the risk factors. imoportantly, with the gradual opening of a two-child policy, more and more chinese women of reproductive age enter pregnancy have a history of gdm. our previous study showed that regular exercise commenced in early pregnancy is effective in reducing the risk of developing gdm in chinese overweight and obese pregant women. thus, in this study, we want to evaluate the effect of lifestyle intervention with detailed information on how to eat and how to diet in preventing the recurrence of gdm

Eligibility criteria:
inclusion criteria: * singleton; * non-smoking ; * before 12+6 weeks gestation. exclusion criteria: * less than 18 years old; * unwilling to provide informed consent; * cervical insufficiency; * women on any medication for pre-existing hypertension, diabetes, cardiac disease, renal disease, systemic lupus erythematosus, thyroid disease or psychosis; * women who were currently being treated with metformin or corticosteroids.
crp and pct as predictors of sepsis cause

Conditions: Sepsis; Gram-Positive Bacteremia; Gram-negative Bacteremia

Summary: the aim of this retrospective study is to determine the predictive role of serum level of procalcitonin (pct) and c-reactive protein (crp) in determining the causative agent of sepsis in surgical intensive care unit (icu) patients. the main question it aims to answer is: what serum level of pct and crp is predictive of gram+ and gram- sepsis in patients with positive blood cultures in the surgical icu. the study will be retrospective and will include all patients with positive blood cultures who were hospitalized in the surgical icu of university hospital osijek in the period from january 2019 to may 2022.

pct is a good biochemical marker of severe bacterial infection. numerous studies have confirmed its role in the diagnosis of sepsis, especially sepsis with positive blood cultures. this retrospective study will include septic patients who were hospitalised in the surgical icu between january 2019 and may 2022, and who had at least one positive blood culture. the values of pct, crp, white blood cells count and platelets count, as well as the overall outcome of the treatment, will be recorded for the patients included in the research. the aim of the research is to examine the differences in the level of pct, crp, white blood cells count and platelets count between patients with gram+ and gram- blood cultures. also, the predictive value of pct and crp in differentiating gram+ from gram- hem will be examined.

Eligibility criteria:
inclusion criteria: * hospitalisation in surgical icu * diagnosis of sepsis * gram+ blood culture isolate * gram- blood culture isolate exclusion criteria: * younger of 18 years old
association between treatment adherence and treatment adherence in sleep apnea (semsas)

Conditions: Obstructive Sleep Apnea

Summary: the objective of the study is to define an optimal threshold of the semsa-15 scale for obstructive sleep apnea (osa) perception in patients with osa to predict 3-month and 1-year continuous positive airway pressure adherence.


Eligibility criteria:
inclusion criteria: * obstructive sleep apnea diagnosed, whatever the initial severity and treated with cpap * voluntary patient * patient in the national healthcare insurance system exclusion criteria: * patient with central sleep apnea * treatment other than cpap * person with liberty privation or under legal protection
evaluating the value of audio-guided meditation during breast biopsy procedures

Conditions: Breast Disease

Summary: a prospective, non-randomized, single-center cohort study to evaluate the value of audio-guided meditation during breast biopsy procedures. the main criterion of judgment is based on the evaluation of tolerance, which includes anxiety and pain felt. this is assessed with questionnaires (stai-etat and en) before and after the procedure. secondary endpoints include tolerance of additional physical pain, reduction in the number of per-procedure complications, overall satisfaction of the practitioner with the biopsy procedure, and comparison of the tolerance of the procedure in patients who practice meditation at home before the procedure

audio-guided meditation during breast biopsy procedures questionnaires (stai-etat and en) before and after the procedure.

Eligibility criteria:
inclusion criteria: * breast pathology requiring the performance of one (or more) breast and/or axillary micro or macrobiopsy, * informed patient, with collection of the non opposition exclusion criteria: * excluded forms of the disease: biopsy concerning organs other than the breast and/or axilla * persons deprived of their liberty, under court protection, under curatorship or under the authority of a guardian, * impossibility to submit to the medical follow-up of the trial for geographical, social or psychic reasons (invalidating psychiatric disorder diagnosed of psychotic type).
efficacy and safety of idelalisib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab for previously untreated chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: the primary objective of this study is to evaluate the effects of idelalisib with obinutuzumab versus the combination of chlorambucil and obinutuzumab on progression-free survival (pfs) in participants with previously untreated chronic lymphocytic leukemia (cll). an increased rate of deaths and serious adverse events (saes) among participants with front-line cll and early-line indolent non-hodgkin lymphoma (inhl) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (dmc) during regular review of 3 gilead phase 3 studies. gilead reviewed the unblinded data and terminated those studies in agreement with the dmc recommendation and in consultation with the us food and drug administration (fda). all front-line studies of idelalisib, including this study, were also terminated.


Eligibility criteria:
key inclusion criteria: * not a candidate for fludarabine therapy based on either: 1. creatinine clearance \< 70 ml/min, or 2. cumulative illness rating scale score \> 6, by assessment of the investigator * diagnosis of b-cell cll, with diagnosis established according to international workshop on chronic lymphocytic leukemia (iwcll) * no prior therapy for cll other than corticosteroids for disease complications. * cll that warrants treatment * presence of measurable lymphadenopathy * eastern cooperative oncology group (ecog) performance status of ≤ 2 key exclusion criteria: * known histological transformation from cll to an aggressive lymphoma (ie, richter transformation) * known presence of myelodysplastic syndrome * evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization * ongoing liver injury * ongoing drug-induced pneumonitis * ongoing inflammatory bowel disease * history of prior allogeneic bone marrow progenitor cell or solid organ transplantation * ongoing immunosuppressive therapy other than corticosteroids * concurrent participation in another therapeutic clinical trial * undergone major surgery within 30 days prior to randomization * known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for idelalisib, obinutuzumab, or chlorambucil * history of non-infectious pneumonitis * received last dose of study drug on another therapeutic clinical trial within 30 days prior to randomization note: other protocol defined inclusion/exclusion criteria may apply.
oxaliplatin and capecitabine versus follow-up after resection of colorectal liver metastases

Conditions: Colorectal Neoplasms; Liver Metastases

Summary: primary endpoint of the study is to prove the superiority of an adjuvant therapy with oxaliplatin/ capecitabine until the first occurrence of appearance of a tumour. occurrences in the meaning of this study are the appearance of a relapse of the tumour, of metastases, of a second tumour or death of any reason.

prospective, randomized, multi-centre, open phase iii study with two parallel groups of patients according to the eligibility criteria. the times in both hierarchical classified endpoints will be measured as times from randomization. patients with macroscopic complete resection of colorectal liver metastases will be randomized in: arm a: post-operative adjuvant therapy with capecitabine/ oxaliplatin over 6 months and follow-up or arm b: follow-up randomization: stratification after scores of fong et al: * number of metastases (1 vs. \>=1) * maximal diameter of the metastasis (\ 5cm) * disease free interval (\>= 12 months vs. \> 12 months) * cea (\ 200 ng/l) in the strata 0-1, 2 and \>= 3,

Eligibility criteria:
inclusion criteria: * patients after r0-resection of colorectal liver metastases * age: \>= 18 years * karnofsky-index \>= 70% * neutrophiles \>1,5 x10e9/l, thrombocytes 100 x10e9/l * adequate contraception for male and female patients * oral and written informed consent (gcp) exclusion criteria: * other prior malignancies, except treated in situ-carcinoma of cervix or tumours of skin without indication to a melanoma (or 10 years tumourfree) * other participation in clinical trials within 30 days before randomization * previous chemotherapy (except adjuvant chemotherapy with an interval of \>= 6 months) * creatinine clearance \<50 ml/min * hepatic insufficiency (alat, asat, bilirubin, ap \>5 x upper limit) * peripheral neuropathy \> ctc grade 1 * uncontrolled cardiac insufficiency or angina pectoris * active infections * severe neurological or psychiatric illness * breast-feeding or pregnant women * incapacity to take part in regular visits

Keywords: oxaliplatin capecitabine chemotherapy resection liver metastases liver resection adjuvant
'the effect of adding lfcn block to peng

Conditions: Pain, Postoperative; Pain, Acute; Nerve Block; Opioid Consumption

Summary: the incidence of femoral neck fracture in europe is 330/10000 per year. it is increasing every year due to the aging of the population. in patients 55 years and older, hip fracture-related mortality is estimated to be between 4% and 16% at one month and between 11% and 43% at one year after surgery. the reduced risk of postoperative complications associated with the use of regional anesthesia, shorter mobilization times, and reduced morphine consumption in hip fractures have been reported, and have been incorporated into postoperative pain control as part of multimodal strategies. peng has been described for postoperative pain control for surgery on the hip joint or for the treatment of post-traumatic pain associated with proximal femur/femoral head fractures. lateral femoral cutaneous nerve block is used in combination with other peripheral block methods to provide analgesia in the lateral thigh. the investigators aimed to evaluate the effect of adding lateral femoral cutaneous nerve block to peng block on pain scores and opioid consumption in femoral fracture procedures under spinal anesthesia.


Eligibility criteria:
inclusion criteria: * 18-75 years old, * asa i-ii-iii risk group * patients undergoing hip fracture surgery under spinal anesthesia * patients whose informed consent was read and consent was obtained from them and their representatives. exclusion criteria: * those who do not want to participate in the study, * asa iv-v patients * those with coagulation disorders * allergic to local anesthetics

Keywords: lateral femoral cutaneous nerve block peng block pain management opioid consumption
integrating supportive care in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: individuals living with cystic fibrosis (cf) commonly report high symptom burden, poor quality of life, and additional psychosocial stressors; these burdens are particularly heightened in advanced stages of the disease. although supportive care (aka palliative care) has been shown to improve many of these outcomes among patients with illnesses such as cancer, no clinical trials to date have tested the impact of supportive care for patients with cf. the purpose of this pilot randomized clinical trial study is to evaluate the feasibility, acceptability, and perceived effectiveness of an embedded supportive care intervention, whereby a supportive care specialist will be integrated within the usual care experience of patients with advanced cf. the investigators will enroll 50 patients with advanced cf, who will be equally randomized to receive this embedded supportive care intervention or usual care. secondary measures include: patient quality of life, mood, coping style, satisfaction with care, and symptom burden. this study will provide preliminary data to support the development of a larger, definitive, phase iii randomized clinical trial.

as described above.

Eligibility criteria:
inclusion criteria: * ability to comprehend english * advanced cf (any of the following criteria will be indicative of "advanced cf") * baseline supplemental oxygen requirement * fev1 ≤ 50% * baseline non-invasive mechanical ventilation requirement * ≥ 2 hospitalizations in the past 12 months for respiratory complications related to cf exclusion criteria: * prisoners * females who are pregnant * prior receipt of specialist sc services * cognitive impairments * patients younger than 18 years of age

Keywords: pulmonary cystic fibrosis
modified-folfirinox regimen based neoadjuvant therapy in chinese patients with locally advanced pancreatic cancer

Conditions: Pancreatic Cancer; Chemotherapy Effect; Surgery--Complications

Summary: folfirinox regimen is first-line neoadjuvant chemotherapies for patients with locally advanced pancreatic cancer (lapc) worldwide. however, folfirinox is not well accepted in china because of the high prevalence of adverse events and poor tolerance. to evaluate the safety and efficacy of modified-folfirinox (mfolfirinox) in chinese lapc patients and compare survival between lapc patients with mfolfirinox-based preoperative therapy and lapc patients who underwent surgery alone.

at this institution, a mfolfirinox regimen has been adopted for metastatic pancreatic cancer (mpc) patients and promising results obtained. the modification resulted in a significantly reduced prevalence of severe adverse events in mpc patients, whereas the os and pfs were extended to 10.3m and 7.0m, respectively, which is similar to that for patients on a full-dose regimen. therefore, the investigators further evaluated the efficacy of mfolfirinox in lapc patients. here, investigators want to prospectively enroll lapc patients who underwent preoperative therapy with mfolfirinox from april 2014 and compared the surgical resectability and surgical morbidity/surgical mortality among patients with surgically resectable pancreatic cancer (rpc) or lapc who underwent surgery alone retrospectively. for patients with lapc, mfolfirinox was administrated for several cycles until the optimal response was obtained and then patients were evaluated for surgery. moreover, survival data, including os and pfs, were determined.

Eligibility criteria:
inclusion criteria: 1. the patients are diagnosed by histology to have pancreatic adenocarcinoma 2. the patients are defined as locally advanced pancreatic cancer according to nccn guideline 3. the patients prescribed mfolfirinox-based neoadjuvant therapy exclusion criteria: 1. ecog performance score more than 2 2. insufficient bone marrow, liver and renal function 3. patients with other malignancies 4. patients were older than 85 years or less than 18 years

Keywords: folfirinox pancreatic cancer conversion surgery overall survival
does homebrewing beer affect urinary tract symptoms and bladder cancer

Conditions: Addiction, Alcohol; Urinary Tract Disease

Summary: in this study, investigators aim to reveal the harmful effects of increasing consumption of homemade beer in recent years on the urinary tract. the high amount of carbonyl compounds in the content of homemade beer has been proven by studies. in this study, which will be conducted in the form of a questionnaire, it is aimed to evaluate the effects of the consumption of homemade beer and the long-term exposure of the urinary system to carbonyl compounds.

homemade and craft beers are perceived as a popular alternative to beers produced on a larger scale in recent years, due to the choice of consumers according to different taste preferences and the raw materials used for brewing. according to nationally representative survey data from the american homebrewers association (aha), the u.s. had an estimated 1.1 million homebrew brewers in 2017, with annual homebrew beer production in excess of 1.4 million barrels (about 1% of annual u.s. beer production). again in 2017, 40% of home brewers started production within the last 4 years. due to the prohibitions that have arisen due to the pandemic all over the world, the production of homemade beer has reached its peak today. in recent years, home-made beer consumption has gained popularity in parallel with low-alcohol and non-alcoholic beers, which are prone to microbial spoilage, due to the ease of access to the material, financial returns and hobby acquisition. homemade beer is typically more susceptible to spoilage as it is not pasteurized or sterile filtered. the microbiota, which is associated with organic raw materials, fruits, herbs, honey, spices and vegetables, and non-traditional starch-rich ingredients added to produce different aromas and flavors, increases the risk of spoilage. in addition, home brewers often lack the advantages of a sophisticated microbiological laboratory, and optimal temperature control during brewing and storage cannot be guaranteed. in addition to the fermentation conditions (time and temperature), yeast strain and mash composition (types of grain used in malting, mashing/boiling conditions) can also affect the chemical profile of beer, resulting in a wide variety of components. carbonyl compounds \[acetaldehyde, acrolein, ethyl carbamate (ec) and formaldehyde\] are particularly toxic compounds that can occur. acetaldehyde, acrolein, and formaldehyde are highly reactive due to their electrophilic nature, so they easily react with biological nucleophilic targets such as proteins, rna, and dna.

Eligibility criteria:
inclusion criteria: * homemade beer consumption and not consumption exclusion criteria * bleeding disorders

Keywords: beer urinary tract
comparison of outcomes between warshaw and kimura techniques for spleen-preserving minimally invasive distal pancreatectomy

Conditions: Distal Pancreatectomy; Spleen Preservation; Postpancreatectomy Hemorrhage

Summary: spleen-persevering distal pancreatectomy (sp-dp) has been widely advocated as a routine procedure for benign or low-grade malignant tumors in the pancreatic body and tail, especially with a minimally invasive approach. spleen preservation can be accomplished with kimura technique (kt) or warshaw technique (wt) both of the two techniques were proved to be feasible and efficient. however, the perioperative outcomes and long-term benefits between patients with kt and wt in spleen-persevering minimally invasive distal pancreatectomy (sp-midp) remains controversial. several small series have reported a slightly higher prevalence of postpancreatectomy hemorrhage (pph) in patients who undergo kt than those undergo wt. the exposure of splenic vessels to erosive pancreatic juice and the preservation of splenic vessels itself may explain the higher chance of pph in kt. larger volume studies are warranted to confirm this finding and to clarify the clinical significance. this study compared the perioperative outcomes between the two spleen-preserving techniques, with a focus on parameters relating to perioperative patient safety. especially, the incidence and clinical relevance of pph in sp-midp were evaluated.


Eligibility criteria:
inclusion criteria: * pathological diagnosis of benign or low-grade malignant pancreas tumors. exclusion criteria: * incomplete medical records, * history of previous splenectomy, * high-grade malignant pancreas tumors, * conversion to open dp (odp).
proton boost in prostate cancer

Conditions: Cancer of the Prostate

Summary: this study uses photon radiation with a proton boost to treat prostate cancer. the purpose of this study is to determine if proton therapy as a boost following photon intensity modulated radiation therapy (imrt) produces decreased toxicity as compared to conventional photon imrt alone in the treatment of prostate cancer. our secondary objective is to determine the effectiveness of this treatment regimen. effectiveness will be determined by length of time to progression or recurrence of disease and overall survival. patients on this study will be treated with a course of photon radiation therapy followed by a boost course of proton radiation.


Eligibility criteria:
inclusion criteria: * ≥18 years of age * diagnosis of low risk prostate cancer (t1c-t2a, gleason 6, prostate specific antigen (psa) \<10) -or- * diagnosis of intermediate risk prostate cancer (t1c-t2c, gleason 7 and/or psa 10- 20) * life expectancy \>10 yrs * physically and mentally capable of signing the consent form of their own volition exclusion criteria: * \< 18 years of age * diagnosis of high risk prostate cancer (t3 or higher, gleason \>7 and/or psa \>20) * current or historical use of androgen deprivation therapy * nodal positivity * previous cancer excluding non-melanoma skin cancer * history of prostatectomy * history of brachytherapy for prostate cancer * life expectancy \<10 yrs * physically or mentally incapable of signing the consent form of their own volition

Keywords: radiation therapy proton therapy